Drug Trial Radar · NCT04665206
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Mar 24, 2021
Primary completion
Nov 2, 2029
Study completion Mar 2, 2030
Sponsor
- Lead sponsor
- Vivace Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Conditions
- Solid Tumor, Adult
- Mesothelioma
- NSCLC
- Pleural Mesothelioma
- Non-Pleural Mesothelioma
- Non Small Cell Lung Cancer
- Epithelioid Hemangioendothelioma (EHE)
- Adenoma
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms, Mesothelial
Interventions
VT3989Drug
25, 50, 100, 150 or 200 mg for oral administration.
Nivolumab & IpilimumabDrug
Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion
OsimertinibDrug
40 or 80 mg tablets for oral administration
Pemetrexed/CarboplatinDrug
Pemetrexed infusion: 500 mg/m2 intravenous infusion Carboplatin infusion: AUC 5.0 intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting ToxicityTime frame: over the first 21 days of dosing
- Occurrence of General ToxicityTime frame: through study completion, an average of 30 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
Virginia Cancer Specialists, PC
Arlington, Virginia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Peter MacCullum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.